United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
Fundamentals
Mkt Cap
$24.88B
Volume
-
52W High
$614.23
52W Low
$455.63
PE Ratio
22.04
Avg. Volume
755,700.94
EPS (Annual)
$27.86
P/B
3.94
Rev/Employee
$2,273,357.14
Earnings
Nov 04
34
Bearish Sentiment
How do you feel about UTHR?
StocktwitsEarnings
$UTHR Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of $5.71 down -20.25% YoY
• Reported revenue of $832.5M up 4.13% YoY
1
GweiGamma
$UTHR quietly grinding higher while biotech sentiment keeps improving. Pulmonary hypertension space getting more attention as pipeline plays mature across the sector. Specialty pharma names like this tend to benefit when risk appetite comes back. Long term setup looks solid here.
shoc24
$UTHR reported earnings before the open today. GAAP EPS missed estimates: $5.71 vs. $6.01 expected, according to Stock Meadow.
Link your Stocktwits account
Ask your agent for live sentiment, watchers, trending tickers, and news.